Maintenance outage: This site will be inaccessible from late evening Mar 7th thru Mar 8th. This is for scheduled technology upgrades by our global hosting service that are affecting numerous websites and online journals. Note that our submission site is still accessible during this period and processing of new submissions will not be affected.
Article Information
History
- July 15, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Author Information
- Shabir A. Madhi, Ph.D.1,2,†,
- Gaurav Kwatra, Ph.D.*,1,2,
- Jonathan E. Myers, M.D.3,
- Waasila Jassat, M.Med.4,5,
- Nisha Dhar, Ph.D.1,
- Christian K. Mukendi, M.Sc.1,
- Lucille Blumberg, M.Med.4,5,
- Richard Welch, B.Sc.4,5,
- Alane Izu, Ph.D.1,2,* and
- Portia C. Mutevedzi, Ph.D.1,*
- 1South African Medical Research Council Vaccines and Infectious Diseases Analytics Research Unit, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 2African Leadership in Vaccinology Expertise, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa
- 3Centre for Environmental and Occupational Health Research, School of Public Health and Family Medicine, University of Cape Town, Cape Town, South Africa
- 4National Institute for Communicable Diseases, Johannesburg, South Africa
- 5Right to Care, Pretoria, South Africa
- ↵†Corresponding author:
Shabir A. Madhi, University of the Witwatersrand, Phillip Tobias Building., Princess of Wales St., Parktown, 2193, Gauteng, South Africa. Cell: +27 (82) 8706672. Email: shabir.madhi@wits{at}ac.za
↵* Equal contribution to the study
Posted July 15, 2022.
SARS-CoV-2 infections during Omicron (BA.1) dominant wave and subsequent population immunity in Gauteng, South Africa
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos